Lasers can reduce retinal thickening

Article

Among diabetic macular oedema (DME) patients, those with diffuse retinal thickening (DRT) experience greater reductions in retinal thickening after undergoing focal laser photocoagulation when compared with either cystoid macular oedema (CME) or vitreomacular interface abnormalities (VMIA) patients, according to a study published online ahead of print by the British Journal of Ophthalmology.

Among diabetic macular oedema (DME) patients, those with diffuse retinal thickening (DRT) experience greater reductions in retinal thickening after undergoing focal laser photocoagulation when compared with either cystoid macular oedema (CME) or vitreomacular interface abnormalities (VMIA) patients, according to a study published online ahead of print by the British Journal of Ophthalmology.

Na Rae Kim of Inha University Hospital, the Republic of Korea, and colleagues examined 70 eyes, all undergoing laser photocoagulation for significant macular oedema, to identify if optical coherence tomography (OCT) patterns could predict visual outcome in these patients. Based on features of the preoperative macular OCT images, examined retrospectively, patients were classified into four categories: DRT, CME, serous retinal detachment (SRD) and VMIA. The team compared retinal thickness and volume and visual acuity (VA) pre- and postoperatively for each of the four groups.

For the different OCT types, the researchers found a statistically significant difference in retinal changes: p=0.002 for retinal thickness and p

The researchers therefore concluded that, because of these differences in response between the groups, using OCT to gain accurate preoperative classification of the grade of DME will allow for greater predictability of outcome.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.